+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032- Product Image
Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032- Product Image
New

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 191 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010624
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Immunotherapy Drugs Market is experiencing dynamic transformation, shaped by rapid scientific innovation, stricter regulatory frameworks, and evolving operational demands. Senior leaders must navigate complex clinical, manufacturing, and market access landscapes to unlock meaningful value and ensure sustained patient benefit.

Market Snapshot: Cancer Immunotherapy Drugs Market

The Cancer Immunotherapy Drugs Market grew from USD 271.88 billion in 2025 to USD 294.63 billion in 2026. It is projected to achieve an 8.62% CAGR, reaching USD 485.22 billion by 2032. This momentum is underpinned by robust investment in immune system-based cancer treatments, increased adoption across diverse oncology indications, and the scaling of advanced biotechnologies in both pharma and biotech sectors.

Scope & Segmentation

  • Mechanisms of Action: Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4), engineered T cell therapies, cancer vaccines, cytokine therapies, and oncolytic viruses.
  • Indication/Oncology Segment: Hematologic malignancies (leukemia, lymphoma, multiple myeloma) and solid tumors (lung, melanoma, bladder), with growing focus on personalized approaches.
  • Treatment Line: First-line, second-line, and later lines, each with unique evidence and tolerability requirements.
  • Route of Administration: Intravenous, oral, and subcutaneous formulations suited for varied institutional, ambulatory, and specialty clinic environments.
  • Distribution and Care Settings: Hospitals, ambulatory care centers, specialty clinics, with channels spanning hospital, online, and retail pharmacies.
  • Geography: Americas, Europe, Middle East & Africa, Asia-Pacific, each with distinct regulatory, infrastructure, and payer dynamics.
  • Technology Platforms: Single-cell profiling, spatial biology, gene editing, vector engineering, and modular manufacturing techniques driving product evolution.

Cancer Immunotherapy Drugs Market: Key Takeaways

  • Immuno-oncology has shifted from experimental status to a cornerstone of clinical cancer care, with streamlined integration of scientific progress, regulatory changes, and innovative operational models.
  • Commercialization strategies increasingly require aligning biomarker-driven development, scalable production, and patient-centric delivery to address real-world constraints and payer expectations.
  • Manufacturers are responding to global trade and policy pressures by regionalizing supply chains, qualifying alternative raw material sources, and adopting modular, flexible production to safeguard continuity.
  • Digital health and real-world data collection are integrated across development and patient management, improving trial efficiency, safety, and treatment adherence monitoring.
  • Regional complexity necessitates tailored approaches—Americas and Asia-Pacific prioritize rapid clinical translation and local manufacturing; Europe, Middle East & Africa demand navigation of fragmented reimbursements and infrastructure disparities.

Tariff Impact and Supply Chain Resilience

Recent trade policies have intensified the need for supply chain resilience in complex biologic and cell therapies. Manufacturers now diversify suppliers, adopt dual sourcing, and invest in regional production to mitigate disruptions from tariffs affecting critical materials such as bioreactor plastics, viral vectors, and cold-chain infrastructure.

Methodology & Data Sources

This report integrates primary interviews with clinical investigators, regulatory experts, manufacturing leaders, and commercial executives. Secondary research covers peer-reviewed literature, trial registries, regulatory filings, and scientific conference data. Data triangulation validates insights, combining qualitative feedback with operational metrics and real-world outcomes.

Why This Report Matters

  • Equips decision-makers with actionable segmentation and trend analysis to inform investment, clinical, and commercialization strategies in the cancer immunotherapy sector.
  • Clarifies how regulatory shifts, manufacturing innovations, and payer expectations converge to shape therapy adoption and operational planning globally.
  • Supports risk mitigation by highlighting supply chain, infrastructure, and partnership imperatives unique to advanced biologic therapies.

Conclusion

Navigating the Cancer Immunotherapy Drugs Market demands seamless integration of science, operations, and commercial strategy. Senior stakeholders can leverage these insights to capitalize on disruptive innovation while delivering durable patient access and value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Immunotherapy Drugs Market, by Therapy Type
8.1. Checkpoint Inhibitors
8.2. Monoclonal Antibodies (Non-Checkpoint)
8.2.1. Naked Monoclonal Antibodies
8.2.2. Antibody Drug Conjugates
8.2.3. Bispecific Antibodies
8.3. Adoptive Cell Therapies
8.3.1. CAR-T Cell Therapies
8.3.2. TCR-T Cell Therapies
8.3.3. Tumor-Infiltrating Lymphocyte Therapies
8.4. Cancer Vaccines
8.4.1. Therapeutic Cancer Vaccines
8.4.2. Prophylactic Cancer Vaccines
8.5. Cytokine Therapies
8.5.1. Interleukin-Based Therapies
8.5.2. Interferon-Based Therapies
8.6. Oncolytic Virus Therapies
9. Cancer Immunotherapy Drugs Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Cancer Immunotherapy Drugs Market, by Cancer Type
10.1. Solid Tumors
10.1.1. Lung Cancer
10.1.1.1. Non-Small Cell Lung Cancer
10.1.1.2. Small Cell Lung Cancer
10.1.2. Melanoma
10.1.3. Breast Cancer
10.1.4. Genitourinary Cancers
10.1.4.1. Renal Cell Carcinoma
10.1.4.2. Bladder Cancer
10.1.4.3. Prostate Cancer
10.1.5. Gastrointestinal Cancers
10.1.5.1. Colorectal Cancer
10.1.5.2. Gastric Cancer
10.1.5.3. Hepatocellular Carcinoma
10.1.5.4. Pancreatic Cancer
10.1.6. Head And Neck Cancers
10.1.7. Gynecological Cancers
10.2. Hematologic Malignancies
10.2.1. Leukemias
10.2.1.1. Acute Lymphoblastic Leukemia
10.2.1.2. Acute Myeloid Leukemia
10.2.1.3. Chronic Lymphocytic Leukemia
10.2.1.4. Chronic Myeloid Leukemia
10.2.2. Lymphomas
10.2.2.1. Hodgkin Lymphoma
10.2.2.2. Non-Hodgkin Lymphoma
10.2.3. Multiple Myeloma
11. Cancer Immunotherapy Drugs Market, by Mechanism Of Action
11.1. Immune Checkpoint Blockade
11.2. Immune Cell Engagers
11.2.1. Bispecific T Cell Engagers
11.2.2. Bispecific NK Cell Engagers
11.3. Immune System Modulators
11.3.1. T Cell Activators
11.3.2. NK Cell Activators
11.3.3. Dendritic Cell Activators
11.4. Tumor Microenvironment Modulators
11.4.1. Angiogenesis Modulators
11.4.2. Myeloid Cell Modulators
11.4.3. Stromal Modulators
11.5. Oncolytic And Lytic Agents
11.6. Cancer Antigen Targeting
12. Cancer Immunotherapy Drugs Market, by End User
12.1. Ambulatory Care Centers
12.2. Hospitals
12.3. Specialty Clinics
13. Cancer Immunotherapy Drugs Market, by Distribution Channel
13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies
14. Cancer Immunotherapy Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Cancer Immunotherapy Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Cancer Immunotherapy Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Cancer Immunotherapy Drugs Market
18. China Cancer Immunotherapy Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie, Inc.
19.6. Amgen Inc.
19.7. Astellas Pharma Inc.
19.8. AstraZeneca PLC
19.9. Bayer AG
19.10. Boehringer Ingelheim International GmbH
19.11. Bristol Myers Squibb Company
19.12. CARsgen Therapeutics
19.13. Celldex Therapeutics, Inc.
19.14. ElevateBio
19.15. ELI Lilly and Company
19.16. F. Hoffmann-La Roche Ltd
19.17. Gilead Sciences, Inc.
19.18. GlaxoSmithKline PLC
19.19. Ikena Oncology
19.20. Incyte Corporation
19.21. Johnson & Johnson Services, Inc.
19.22. Merck & Co., Inc.
19.23. Novartis AG
19.24. OSE Immunotherapeutics SA
19.25. Pfizer Inc.
19.26. QIAGEN N.V.
19.27. Sanofi SA
19.28. Seattle Genetics Inc.
19.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKIN-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKIN-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKIN-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERON-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERON-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERON-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTRIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTRIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GYNECOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GYNECOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GYNECOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC NK CELL ENGAGERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC NK CELL ENGAGERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC NK CELL ENGAGERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY T CELL ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY T CELL ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY T CELL ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANGIOGENESIS MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANGIOGENESIS MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 187. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANGIOGENESIS MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MYELOID CELL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MYELOID CELL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 190. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MYELOID CELL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STROMAL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STROMAL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 193. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STROMAL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC AND LYTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC AND LYTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 196. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC AND LYTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER ANTIGEN TARGETING, BY REGION, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER ANTIGEN TARGETING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 199. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER ANTIGEN TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 202. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 203. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 205. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 208. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 209. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 212. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 215. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 218. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 221. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 222. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 223. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
TABLE 224. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 225. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 226. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 227. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 229. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 230. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 231. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
TABLE 232. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
TABLE 233. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 234. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
TABLE 235. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
TABLE 236. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 237. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
TABLE 238. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
TABLE 239. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
TABLE 240. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 244. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
TABLE 245. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 246. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 247. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 248. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 250. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 251. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 252. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
TABLE 253. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
TABLE 254. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 255. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
TABLE 256. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
TABLE 257. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 258. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
TABLE 259. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
TABLE 260. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
TABLE 261. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 264. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 265. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
TABLE 266. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 267. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 268. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 269. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 271. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 272. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 273. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
TABLE 274. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
TABLE 275. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 276. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
TABLE 277. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
TABLE 278. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 279. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
TABLE 280. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
TABLE 281. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
TABLE 282. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 283. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRIC

Companies Mentioned

The key companies profiled in this Cancer Immunotherapy Drugs market report include:
  • AbbVie, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • CARsgen Therapeutics
  • Celldex Therapeutics, Inc.
  • ElevateBio
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Ikena Oncology
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OSE Immunotherapeutics SA
  • Pfizer Inc.
  • QIAGEN N.V.
  • Sanofi SA
  • Seattle Genetics Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages191
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 294.63 Billion
Forecasted Market Value ( USD ) by 2032 $ 485.22 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Cancer Immunotherapy Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Cancer Immunotherapy Market Report 2025 - Product Image

Cancer Immunotherapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.